Celsion Corporation (CLSN), Acasti Pharma (ACST) and Heat Biologics (HTBX) Emerge as Losers among Biotech Stocks

Celsion Corporation
Celsion Corporation

Being an oncology drug development company,An agreement for load between Celsion Corporation (NASDAQ:CLSN) and Hercules Technology Growth Capital, Inc., has been signed; the loan will allow $20 million in capital distributable. With the agreement’s closing on the 25th of November, Celsion Corporation (NASDAQ:CLSN) got its first tranche worth $5 million. Shares of Celsion Corporation (NASDAQ:CLSN) ended at a value of $36.56 yesterday. Institutional ownership of the stock is 15.00% whereas its insider ownership is 0.80%. Stock’s shares capital has outstanding shares of 12.09 billion out of which shares of 13.38 billion are being floated in the market.

An IPO of 16 million Acasti units at a value of $1.25 a unit will be held by Acasti Pharma Inc (NASDAQ:ACST). Each unit at IPO will have a purchase warrant for one share from Class A and one from Common Share of Acasti Pharma Inc (NASDAQ:ACST). Shares of Acasti Pharma Inc (NASDAQ:ACST) kicked off its day’s session at $1.28 and went up as high as $1.28; after dipping by -13.68% towards the session’s end the stock closed at a value of $1.20. Stock’s weekly performance was -22.58%.

Heat Biologics Inc (NASDAQ:HTBX) has successfully completed its investigational GMP-grade batch of HS-410 drug. Shares of Heat Biologics Inc (NASDAQ:HTBX) had a volume share of 46,432.00 during the session’s trading where its average volume share is 31,250.00. Shares of Heat Biologics Inc (NASDAQ:HTBX) kicked off at a value of $9.18 and went up as high as $9.30; after dipping by -8.62% the stock closed at $8.38.